1. Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps

   • Hassan Aziz
   • D. Brock Hewitt
   • Timothy M. Pawlik

   ASO Perspectives 13 April 2022 Pages: 3363 - 3365

   

2. Repeat CRS/HIPEC: It Comes Down to Tumor Biology and Ability to Achieve a Complete CRS

   • Konstantinos I. Votanopoulos

   Peritoneal Surface Malignancy 18 February 2022 Pages: 3366 - 3368

3. Deciphering the Etiology of Weight Loss Following Pancreatectomy

   • Zhi Ven Fong
   • Motaz Qadan

   Pancreatic Tumors 04 February 2022 Pages: 3369 - 3370

4. First Differentiate and Then Operate (Or Not)

   • Xavier M. Keutgen

   Endocrine Tumors 01 March 2022 Pages: 3371 - 3372

5. Editorial Comment to “High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study”

   • Yoshihide Nanno
   • Hirochika Toyama

   Pancreatic Tumors 21 March 2022 Pages: 3373 - 3374

6. Weighing in on Ghrelin and the Preservation of Muscle After Esophagectomy

   • Evan T. Alicuben
   • Anthony W. Kim

   Thoracic Oncology 06 March 2022 Pages: 3375 - 3376

7. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM)

   • Areeba Saif
   • Alexander J. Rossi
   • Jonathan S. Zager

   ASO Research Letter 28 February 2022 Pages: 3377 - 3378

   

8. Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP)

   • Martha E. Teke
   • Alexander J. Rossi
   • Brian Gastman

   ASO Research Letter 08 March 2022 Pages: 3379 - 3380

   

9. Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers

   • Angelin Tresa Mathew
   • Bhav Jain
   • Fumiko Chino

   ASO Research Letter 29 January 2022 Pages: 3381 - 3383

10. A Framework for Reporting Cohort Derivation in Studies Using the National Cancer Database

    • Sarah R. Kaslow
    • Ryan P. Merkow
    • Camilo Correa-Gallego

    ASO Research Letter 03 March 2022 Pages: 3384 - 3386

    

11. Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases

    • Nyan Y. Khin
    • Madhawa De Silva
    • Rodney J. Lane

    ASO Research Letter Open access 11 February 2022 Pages: 3387 - 3389

    

12. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix

    • Felipe Lopez-Ramirez
    • Vadim Gushchin
    • Armando Sardi

    Peritoneal Surface Malignancy 08 February 2022 Pages: 3390 - 3401

    

13. ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer

    • Felipe Lopez-Ramirez
    • Mary Caitlin King
    • Armando Sardi

    ASO Author Reflections 11 January 2022 Pages: 3402 - 3403

14. ASO Visual Abstract: Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix

    • Felipe Lopez-Ramirez
    • Vadim Gushchin
    • Armando Sardi

    ASO Visual Abstract 24 January 2022 Pages: 3404 - 3404

15. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    • Marco Tonello
    • Dario Baratti
    • Antonio Sommariva

    Peritoneal Surface Malignancy 16 November 2021 Pages: 3405 - 3417

    

16. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    • Marco Tonello
    • Antonio Sommariva

    ASO Author Reflections 06 November 2021 Pages: 3418 - 3419

17. ASO Visual Abstract: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

    • Marco Tonello
    • Dario Baratti
    • Antonio Sommariva

    ASO Visual Abstract 31 March 2022 Pages: 3420 - 3421

18. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms

    • Cristian D. Valenzuela
    • Christopher W. Mangieri
    • Perry Shen

    Peritoneal Surface Malignancy 07 March 2022 Pages: 3422 - 3431

    

19. ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm?

    • Cristian D. Valenzuela
    • Konstantinos I. Votanopoulos
    • Perry Shen

    ASO Author Reflections 07 March 2022 Pages: 3432 - 3433

20. ASO Visual Abstract: Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms

    • Cristian D. Valenzuela
    • Christopher W. Mangieri
    • Perry Shen

    ASO Visual Abstract 06 March 2022 Pages: 3434 - 3435

21. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience

    • Cristian D. Valenzuela
    • Edward A. Levine
    • Perry Shen

    Peritoneal Surface Malignancy 14 March 2022 Pages: 3436 - 3445

    

22. ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University

    • Cristian D. Valenzuela
    • Edward A. Levine
    • Perry Shen

    ASO Author Reflections 11 March 2022 Pages: 3446 - 3447

23. ASO Visual Abstract: Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis—A 30-year Institutional Experience

    • Cristian D. Valenzuela
    • Edward A. Levine
    • Perry Shen

    ASO Visual Abstract 07 March 2022 Pages: 3448 - 3449

24. Weight Tracking as a Novel Prognostic Marker After Pancreatectomy

    • Jonathan J. Hue
    • Lee M. Ocuin
    • Sarah C. Markt

    Pancreatic Tumors 23 January 2022 Pages: 3450 - 3459

    

25. ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival

    • Jonathan J. Hue
    • Jordan M. Winter
    • Sarah C. Markt

    ASO Author Reflections 25 January 2022 Pages: 3460 - 3461

26. ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy

    • Jonathan J. Hue
    • Lee M. Ocuin
    • Sarah C. Markt

    ASO Visual Abstract 14 February 2022 Pages: 3462 - 3462

27. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?

    • Kevin M. Turner
    • Aaron M. Delman
    • Sameer H. Patel

    Pancreatic Tumors 09 February 2022 Pages: 3463 - 3472

    

28. ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer

    • Kevin M. Turner
    • Sameer H. Patel

    ASO Author Reflections 06 February 2022 Pages: 3473 - 3474

29. ASO Visual Abstract: Systemic Therapy for Resected Pancreatic Adenocarcinoma—How Much Is Enough?

    • Kevin M. Turner
    • Aaron M. Delman
    • Sameer H. Patel

    ASO Visual Abstract 16 March 2022 Pages: 3475 - 3476

30. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol

    • Giuseppe Malleo
    • Laura Maggino
    • Roberto Salvia

    Pancreatic Tumors Open access 21 February 2022 Pages: 3477 - 3488

    

31. ASO Author Reflection: Location of Nodal Metastases in Pancreatoduodenectomy for Cancer: Which Station Matters?

    • Giuseppe Malleo
    • Laura Maggino
    • Roberto Salvia

    ASO Author Reflections 25 February 2022 Pages: 3489 - 3490

32. ASO Visual Abstract: Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective Lymphadenectomy Protocol

    • Giuseppe Malleo
    • Laura Maggino
    • Roberto Salvia

    ASO Visual Abstract 02 March 2022 Pages: 3491 - 3491

33. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

    • M. Redegalli
    • M. Schiavo Lena
    • C. Doglioni

    Pancreatic Tumors Open access 01 March 2022 Pages: 3492 - 3502

    

34. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System

    • Miriam Redegalli
    • Marco Schiavo Lena

    ASO Author Reflections 20 February 2022 Pages: 3503 - 3503

35. ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

    • Miriam Redegalli
    • Marco Schiavo Lena
    • Claudio Doglioni

    ASO Visual Abstract 21 March 2022 Pages: 3504 - 3504

36. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with Videos)

    • Tomotaka Kato
    • Yosuke Inoue
    • Yu Takahashi

    Pancreatic Tumors 14 February 2022 Pages: 3505 - 3514

    

37. Comment on “Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy”

    • Ayfer Durak
    • Umut Safer

    Pancreatic Tumors 16 March 2022 Pages: 3515 - 3516

38. More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis

    • Anna Burelli
    • Giampaolo Perri
    • Giovanni Marchegiani

    Pancreatic Tumors 19 March 2022 Pages: 3517 - 3518

39. Reply to: Letter to the Editor: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis, by Marchegiani, Giovanni et al.

    • Sebastian Hempel
    • Florian Oehme
    • Marius Distler

    Pancreatic Tumors Open access 25 February 2022 Pages: 3519 - 3520

40. Correction to: Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study

    • Eun-Ki Min
    • Seung Soo Hong
    • Ho Kyoung Hwang

    Correction 15 February 2022 Pages: 3521 - 3521

41. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis

    • Sarah R. Kaslow
    • Gerardo A. Vitiello
    • Camilo Correa-Gallego

    Endocrine Tumors 05 March 2022 Pages: 3522 - 3531

    

42. ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma

    • Sarah R. Kaslow
    • Camilo Correa-Gallego

    ASO Author Reflections 26 February 2022 Pages: 3532 - 3533

43. ASO Visual Abstract: Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma—An NCDB Analysis

    • Sarah R. Kaslow
    • Gerardo A. Vitiello
    • Camilo Correa-Gallego

    ASO Visual Abstract 05 March 2022 Pages: 3534 - 3535

44. Clinical Predictors of Pseudohypoxia-Type Pheochromocytomas

    • J. J. Baechle
    • P. Marincola Smith
    • C. M. Kiernan

    Endocrine Tumors 01 March 2022 Pages: 3536 - 3546

    

45. ASO Author Reflections: Clinical Predictors of Pseudohypoxia Cluster Type Pheochromocytomas

    • Jordan J. Baechle
    • Paula Marincola Smith
    • Colleen M. Kiernan

    ASO Author Reflections 03 April 2022 Pages: 3547 - 3548

46. ASO Visual Abstract: Clinical Predictors of Pseudohypoxia-Type Pheochromocytoma

    • Jordan J. Baechle
    • Paula Marincola Smith
    • Colleen M. Kiernan

    ASO Visual Abstract 21 March 2022 Pages: 3549 - 3550

47. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study

    • Chuan Lan
    • Yo-ichi Yamashita
    • Hideo Baba

    Translational Research 13 April 2022 Pages: 3551 - 3564

    

48. ASO Visual Abstract: High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study

    • Chuan Lan
    • Yo-ichi Yamashita
    • Hideo Baba

    ASO Visual Abstract 22 March 2022 Pages: 3565 - 3566

49. Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival

    • Kiyohiko Omichi
    • Yosuke Inoue
    • Akio Saiura

    Translational Research 03 February 2022 Pages: 3567 - 3576

    

50. ASO Visual Abstract: Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival

    • Kiyohiko Omichi
    • Yosuke Inoue
    • Akio Saiura

    ASO Visual Abstract 03 March 2022 Pages: 3577 - 3577